New hope for patients with deadly bile duct cancer Doctors in the UK are hoping to transform the lives of people with deadly bile duct cancer.
In the new study, patients diagnosed with the three main types of bile duct cancer (intrahepatic, perihilar or distal cholangiocarcinoma) or with cancer of the gallbladder could be eligible to take part in the SAFIR-ABC10 trial.
Bile duct cancer (also called cholangiocarcinoma or biliary tract cancer) starts in the bile ducts, which are the tubes connecting the liver and gallbladder to the small bowel.
Some people on the drugs have seen their cancer go into remission, while others have had previously inoperable cancer become suitable for surgery.
The UK arm of the international work is being run by University College London Hospitals (UCLH) and University College London (UCL), where around 40 people have so far received treatment.
